Financial reports
10-K
2023 FY
Annual report
23 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
10-K
2022 FY
Annual report
27 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
2 May 22
10-K
2021 FY
Annual report
1 Mar 22
Current reports
8-K
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
25 Mar 24
8-K
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25 Mar 24
8-K
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
19 Mar 24
8-K
Corporate Presentation February 2024
20 Feb 24
8-K
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
20 Feb 24
8-K
Corporate Presentation January 2024
8 Jan 24
8-K
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
4 Jan 24
8-K
Other Events
7 Dec 23
8-K
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
6 Nov 23
8-K
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
11 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
28 Jun 23
424B5
Prospectus supplement for primary offering
27 Jun 23
S-8
Registration of securities for employees
23 Jun 23
S-8
Registration of securities for employees
8 May 23
S-3ASR
Automatic shelf registration
2 Dec 22
424B5
Prospectus supplement for primary offering
19 Aug 22
S-8
Registration of securities for employees
2 May 22
424B5
Prospectus supplement for primary offering
1 Mar 22
S-8
Registration of securities for employees
11 May 21
S-8
Registration of securities for employees
11 May 20
Proxies
DEF 14A
Definitive proxy
21 Apr 23
DEF 14A
Definitive proxy
22 Apr 22
DEF 14A
Definitive proxy
23 Apr 21
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEF 14A
Definitive proxy
21 Apr 20
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
DEF 14A
Definitive proxy
28 Apr 17
DEF 14A
Definitive proxy
27 Apr 16
Other
SEC STAFF
SEC staff action: Order
19 Apr 21
SEC STAFF
SEC staff action: Order
22 Mar 21
EFFECT
Notice of effectiveness
16 Dec 16
CORRESP
Correspondence with SEC
15 Dec 16
UPLOAD
Letter from SEC
15 Dec 16
CT ORDER
Confidential treatment order
22 Dec 15
EFFECT
Notice of effectiveness
19 Nov 15
CORRESP
Correspondence with SEC
16 Nov 15
CORRESP
Correspondence with SEC
16 Nov 15
CORRESP
Correspondence with SEC
29 Oct 15
Ownership
4
ROGER JEFFS
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
ROGER JEFFS
29 Feb 24
4
Mark E Saad
29 Feb 24
4
Mark L. Jacobson
29 Feb 24
4
Nick Pizzie
29 Feb 24
4
HERRIOT TABUTEAU
29 Feb 24
4
Susan Mahony
29 Feb 24
4
Hunter R. Murdock
29 Feb 24